Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus PENICILLIN G POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN CLAVULANATE versus PENICILLIN G POTASSIUM.
Amoxicillin-Clavulanate vs PENICILLIN G POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
None Documented
None Documented
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with CrCl <10 mL/min).
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Category C
Category A/B
Penicillin Antibiotic + Beta-Lactamase Inhibitor
Penicillin Antibiotic